Natera (NTRA) commented on recent updates by the NCCN on circulating tumor DNA molecular residual disease testing in the Clinical Practice ...

Natera, Inc. , a global leader in cell-free DNA and genetic testing, today commented on recent updates by the NCCN on circulating tumor DNA (ctDNA) molecular residual disease (MRD) testing in the ...

Canaccord Genuity maintained a Buy rating on Natera (NASDAQ:NTRA) shares, with a price target of $180. Trading at $169.27, the $22.35 billion market cap company enjoys strong analyst support, with a ...

Shares of ANGLE plc (LON:AGL – Get Free Report) traded down 9.4% on Saturday . The company traded as low as GBX 14.22 ($0.18) and last traded at GBX 14.50 ($0.18). 1,973,299 shares were traded during ...

James reaffirmed its Outperform rating and $175.00 price target for Natera (NASDAQ:NTRA), following updates to oncology guidelines that could impact the company's cancer testing product, Signatera.

Rockwell Automation, Inc. today reported first quarter fiscal 2025 results. "Q1 margins and EPS came in well above our expectations this quarter, reflecting some early benefits of Rockwell's renewed ...

In recent weeks, reports have been circulating about severe reactions in people who’ve taken over-the-counter vitamin B6 ...

Megakaryocytes form a three-dimensional (3D) cage composed of laminin and collagen IV connected to the basement membrane surrounding them. This microarchitecture stabilizes megakaryocytes within their ...

Preclinical studies have shown their potential to reduce inflammation and modulate immune responses in diseases like rheumatoid arthritis and lupus.

University of Manitoba independent research verifies that RuvidarTM is more effective than acyclovir in the inactivation of Herpes Simplex Viruses post infection. TORONTO, ON / ACCESS Newswire / Febru ...